Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Several African countries where malaria is widespread are expected to swiftly approve the new medicine following Swissmedic’s ...

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...

IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants.

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...